We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-3.93%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.2B
AUM Growth
-$117M
Cap. Flow
-$19.9M
Cap. Flow %
-1.66%
Top 10 Hldgs %
63.36%
Holding
73
New
12
Increased
16
Reduced
13
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$32M
2
NVO
Novo Nordisk
NVO
+$30.4M
3
IRTC icon
iRhythm Holdings
IRTC
+$18.8M
4
SNY icon
Sanofi
SNY
+$15M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$13.8M

Top Sells

Rank Stock Value
1
ZTS icon
Zoetis
ZTS
+$20.1M
2
UTHR icon
United Therapeutics
UTHR
+$18.9M
3
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$18.3M
4
GH icon
Guardant Health
GH
+$15.9M
5
AZN icon
AstraZeneca
AZN
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 92.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GERN icon
51
CALL
Geron
GERN
$911M
$1.55M 0.13%
1,000,000
– –
CLDX icon
52
Celldex Therapeutics
CLDX
$2.77B
$1.3M 0.11%
+48,304
New +$1.4M
PTGX icon
53
CALL
Protagonist Therapeutics
PTGX
$8.75B
$791K 0.07%
100,000
-100,000
-50% -$1.21M
SYBX
54
DELISTED
Synlogic
SYBX
$661K 0.06%
38,331
– –
PDSB icon
55
PDS Biotechnology
PDSB
$38.1M
$521K 0.04%
142,635
– –
FUSN
56
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$194K 0.02%
78,066
– –
INSM icon
57
Insmed
INSM
$23.2B
$145K 0.01%
7,370
+2,002
+37% +$42K
BCYC
58
Bicycle Therapeutics
BCYC
$270M
– –
-163,559
Closed -$7.18M
FULC icon
59
Fulcrum Therapeutics
FULC
$248M
– –
-229,509
Closed -$5.43M
GH icon
60
Guardant Health
GH
$19.5B
– –
-239,995
Closed -$15.9M
HRTX icon
61
Heron Therapeutics
HRTX
$86.3M
– –
-11,060
Closed -$63K
INKT icon
62
MiNK Therapeutics
INKT
$55.1M
– –
-33,100
Closed -$745K
IWM icon
63
PUT
iShares Russell 2000 ETF
IWM
$80.9B
– –
-150,000
Closed -$30.8M
PFE icon
64
Pfizer
PFE
$140B
– –
-49,378
Closed -$2.56M
PODD icon
65
Insulet
PODD
$11.3B
– –
-1,066
Closed -$284K
PTCT icon
66
PTC Therapeutics
PTCT
$6.37B
– –
-3,480
Closed -$130K
PTGX icon
67
Protagonist Therapeutics
PTGX
$8.75B
– –
-547,441
Closed -$6.62M
QQQ icon
68
PUT
Invesco QQQ Trust
QQQ
$455B
– –
-175,000
Closed -$63.4M
ZTS icon
69
Zoetis
ZTS
$31.6B
– –
-106,574
Closed -$20.1M
ICPT
70
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-100,000
Closed -$1.63M
SRRA
71
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-572,297
Closed -$18.3M
CMPI
72
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
– –
-3,606,707
Closed -$11.5M
1 2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2022 Portfolio in Review

As of Q2 2022, Sofinnova Investments held 73 positions worth $1.2B, down 8.9% from $1.32B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sofinnova Investments's Q2 2022 filing shows 12 new, 16 increased, 13 reduced and 15 closed positions. Its largest new stake was Merck: 360,961 shares worth $32.9M. The largest sale was Zoetis, an estimated $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 89% a quarter earlier.

  • Sofinnova Investments's largest Q2 2022 buy was Merck: 360,961 shares worth $32.9M.
  • Sofinnova Investments added most to Karuna Therapeutics, Inc. Common Stock in Q2 2022, an estimated $13.8M increase.
  • Sofinnova Investments's biggest Q2 2022 reduction was United Therapeutics, cutting an estimated $18.9M.
  • Sofinnova Investments fully exited Zoetis in Q2 2022, selling an estimated $20.1M.
  • Sofinnova Investments's ten largest holdings make up 63% of its $1.2B portfolio in Q2 2022.
  • Sofinnova Investments opened 12 new positions and closed 15 in Q2 2022.
  • Sofinnova Investments's portfolio value fell 8.9% quarter-over-quarter to $1.2B.

Based on Sofinnova Investments's 13F filing for Q2 2022, filed 15 Aug 2022.